SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
Abstract
odium-glucose cotransporter-2 (SGLT2) inhibitors exert outstanding benefits on heart failure (HF) both with reduced ejection fraction (HFrEF) and with preserved ejection fraction.However, the mechanisms of benefit of SGLT2 inhibitors on HF are not completely understood.In this issue of Circulation, Selvaraj et al 1 shed more light on the effect of SGLT2 inhibitors on myocardial energetic and fuel metabolism by leveraging targeted metabolomics in blood samples of the DEFINE-HF trial (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients With HF With Reduced Ejection Fraction).
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
- Diabetes mellitus: an important risk factor for peripheral vascular disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.